Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment
Background. PLK1 overexpression is oncogenic and is associated with poor prognosis in various cancers. However, the current PLK1 inhibitors have achieved limited clinical successes. On the other hand, although immunotherapies are demonstrating efficacy in treating many refractory cancers, a substant...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2018-01-01
|
| Series: | Journal of Oncology |
| Online Access: | http://dx.doi.org/10.1155/2018/3979527 |